a resource of the Bioethics Institute of Loyola Marymount University
THE BIOETHICS HUB
AT THE BIOETHICS INSTITUTE
The Bioethics Hub is a resource for healthcare providers, bioethicists, scholars, and students in Southern California and beyond. There are academic articles, interviews with bioethicists, links to ethics-related news items, and local bioethics events.
This site is managed by the Bioethics Institute at Loyola Marymount University.
April 25, 2023 (LMU)
Over the last decade, there have been several controversial cases involving the authority of advance directives for persons with dementia, relating to voluntarily stopping eating and drinking (VSED) and euthanasia. At play are fundamental questions of who are and how we can respect human dignity. These cases highlight the need for a greater discussion surrounding care for persons with dementia, as we face an aging population.
To read more, click here
March 21, 2023 (LMU)
On Tuesday March 21, esteemed bioethicist and international scholar, Dr. Henk ten Have gave a lecture to students, faculty, and the LMU community on social solidarity, vulnerability, and human rights in a global context. Following the lecture, he, along with Professor Roberto Dell'Oro, answered questions from the audience.
To read more about the lecture, click here.
Professor Roberto Dell'Oro appointed as Ordinary Member of Pontifical Academy for Life, Meets Pope Francis
February 2, 2023 (LMU)
In February, Dr. Dell'Oro had the honor of meeting with the Pope following his appointment as an Ordinary Member of the Pontifical Academy for Life.
To read more, click here.
NATIONAL AND GLOBAL BIOETHICS NEWS, SCHOLARSHIP, AND ISSUES
The Observatory is a monthly collection of special reports and news based on the latest biomedical and biotechnological research findings from the top medical and scientific journals.
July 6, 2023
The FDA on Thursday granted traditional approval to an Alzheimer’s drug for the first time in more than two decades.
Now, the question becomes how many people will be able to access the drug, which is targeted at patients in the early stages of the debilitating disease. Medicare has said that it will reimburse the drug’s costs — more than $26,000 annually — only for beneficiaries enrolled in a nationwide registry that tracks patient side effects and outcomes over time.
Read the article here.
July 6, 2023
Researchers using modern gene-editing tools have discovered that the intuition of scientists from more than a century ago was right: Cells with unusual numbers of chromosomes are drivers of cancer.
The study, published Thursday in the journal Science, renews scientific attention on an old-fashioned idea, one that could point toward new ways to target cancer cells with drugs.